Covid 19 Research using Clinical Trials (Home Page)
Report for D015212: Inflammatory Bowel Diseases NIH
(Synonyms: Inflammatory Bowe, Inflammatory Bowel, Inflammatory Bowel Di, Inflammatory Bowel Disease, Inflammatory Bowel Diseases)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D007410 | Intestinal Diseases NIH | 0.71 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.03 |
Correlated HPO Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002037 | Inflammation of the large intestine HPO | 0.71 |
There are 2 clinical trials
Clinical Trials
1 Prospective Multicenter Cohort of Patients With Inflammatory Bowel Disease Treated by Infliximab or Vedolizumab During COVID-19 Pandemic
Multicenter cohort of patients followed for 6 months during the pandemic in France with biocollection of sera and peripheral blood mononuclear cells
NCT04344249 IBD COVID MeSH:Inflammatory Bowel Diseases
HPO:Inflammation of the large intestine
Primary Outcomes
Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection
Measure: IgG and IgM anti SARS-CoV-2 Time: through study completion, an average of 2 year
Secondary Outcomes
Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
weight (Kg)
height (m)
ABO Group ....
Measure: Clinical factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
Description: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
ACCOMMODATION
HOUSING AREA
number of people at home ....
Measure: demographic factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
Description: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
Measure: pharmacologic factors and severity of COVID-19 infection Time: through study completion, an average of 2 year
2 PREPARE-IBD: Physician Responses to Disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease During COVID-19 Pandemic
Primary Outcomes
Description: Impact of antibodies du to immunosuppressive protocol on the risk of viral infection
Measure: IgG and IgM anti SARS-CoV-2 Time: through study completion, an average of 2 yearSecondary Outcomes
Description: Describe clinical factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. weight (Kg) height (m) ABO Group ....
Measure: Clinical factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe demographic factors of the population of IBD patients treated with vedolizumab or infliximab who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management. ACCOMMODATION HOUSING AREA number of people at home ....
Measure: demographic factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearDescription: Describe residual rates of treatments (edolizumab or infliximab) of the population of IBD patients who develop asymptomatic, pauci-symptomatic non-hospitalized and severe IBD requiring hospital management.
Measure: pharmacologic factors and severity of COVID-19 infection Time: through study completion, an average of 2 yearTo find out what adaptations have been made by Inflammatory bowel disease physicians and patients in relation to therapies in flaring IBD patients during severe acute respiratory syndrome 2-COV and what the impact of these is on IBD patients with no symptomatic COVID-19 and in suspected/confirmed COVID-19. Also whether there any IBD related factors impacting the outcome of patients with COVID-19 symptoms or COVID-19 disease